-
- Nathan P. Staff
- Department of Neurology Mayo Clinic Rochester MN
-
- Anna Grisold
- Department of Neurology Medical University of Vienna Vienna Austria
-
- Wolfgang Grisold
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology Vienna Austria
-
- Anthony J. Windebank
- Department of Neurology Mayo Clinic Rochester MN
説明
<jats:p>Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory‐predominant with pain and can lead to long‐term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772–781</jats:p>
収録刊行物
-
- Annals of Neurology
-
Annals of Neurology 81 (6), 772-781, 2017-06
Wiley
